Skip to content

In the BioHarmony Drug Report Database

Rizatriptan

Maxalt, Maxalt-mlt (rizatriptan) is a small molecule pharmaceutical. Rizatriptan was first approved as Maxalt on 1998-06-29. It is used to treat migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1B and 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1F, and 5-hydroxytryptamine receptor 1A.
Trade Name Maxalt, Maxalt-mlt
Common Name Rizatriptan
Indication migraine disorders
Drug Class Antimigraine agents (5-HT1 receptor agonists),sumatriptan derivatives
Rizatriptan
Get full access now